Pharmacy Times

JULY 21, 2025

Furthermore, by 2030, the proportion of aging among PLWH are set to increase across geographic regions and gender. This trend is similar for patients contracting HIV, according to Wong; currently, 40 million individuals live with HIV worldwide, and among these, almost 10 million are aged 50 years or older.

HIV Treatment and Prevention Agents

PharmTech

JUNE 10, 2025

The global biopharma industry is expected to increase at a compound annual growth rate of 8.97% from 2025 to 2030; this growth is suspected to result from a demand for targeted therapies, new alliances, and increased innovation (1).

Dosage

Drug Topics

JUNE 12, 2025

1 "The label expansion for Mavyret, coupled with the implementation of test and treat models of care, serve as tools to support the public health community in treating more patients and bringing us closer to achieving the global 2030 elimination goal."

FDA

Pharmaceutical Technology

JULY 8, 2025

Go deeper with GlobalData Reports LOA and PTSR Model - Briquilimab in Severe Combined Immune Deficien. Reports LOA and PTSR Model - Immune Globulin (Human) in Chronic Lymphocytic. Reports LOA and PTSR Model - Immune Globulin (Human) in Chronic Lymphocytic. Data Insights The gold standard of business intelligence.

Packaging

Pharma Marketing Network

APRIL 20, 2025

AIDS is the final stage of HIV infection when the bodys immune system becomes severely compromised. With proper antiretroviral treatment, individuals can live 2030 years after an AIDS diagnosis. When a person maintains an undetectable viral load, their immune system remains stronger, and the virus is less likely to progress to AIDS.

Immunization

Pharmaceutical Technology

JULY 24, 2025

It employs a function-first screening workflow to reveal rare and effective immune targets, thereby fast-tracking the next-generation prophylactics and treatments development. Kling-Select provides a powerful window into the human immune response and accelerates the identification of functional antibodies and novel epitopes.

Vaccines

Pharmacy Times

JUNE 12, 2025

4,5 In most cases, HPV infections are short-lived and resolve on their own within 1 to 2 years, as the immune system clears the virus. 5 The vaccine is most effective when given in pre-teen or early teen years when the immune system is most responsive. 5 "There are 3 products on the market,” said Castle.

Vaccines

Pharmaceutical Technology

JULY 14, 2025

A single dose of the vaccine in adults aged 18-49 at increased risk of RSV-LRTD elicited robust immune responses that were non-inferior to those observed in adults aged 60 and above. The global RSV market is set to reach $6.3bn in value by 2030, according to analysis by GlobalData.

Labelling

Drug Topics

JUNE 20, 2025

1 “In line with the goals of its Immunization Agenda 2030, WHO has identified a new list of 17 high-priority global endemic pathogens for vaccine research and development, of which skin pathogens account for at least 8, reinforcing the need for continued focus in this area.”

Vaccines

European Pharmaceutical Review

JUNE 6, 2025

billion by 2030, driven by the rising demand for off-the-shelf therapies that offer scalable, standardised solutions for treating a wide range of diseases, including cancer and auto-immune diseases. Cancer Immunity and Immunotherapy. The global cell therapy market is projected to reach $20.07 Internet] Grand View Research.

Immunization

Pharmaceutical Technology

AUGUST 7, 2025

Meanwhile, GlobalData forecasts that the mRNA vaccine market will continue to grow, increasing in value from $11bn in 2024 to $17.9bn in 2030. Shares of key sector players such as Moderna and BioNTech remain stable, with values reducing by 2.8% and increasing by 0.21% respectively, suggesting that investors still have hope for the modality.

Vaccines

Pharmacy Times

JULY 18, 2025

The study authors noted that an estimated 1 billion individuals are expected to have obesity by 2030. Obesity is defined as a body mass index (BMI) of 30.0 and higher.

Compounding Pharmacies

PharmTech

JUNE 26, 2025

million) in non-dilutive funding through i-Nov, an innovation competition and flagship French government program that is part of the France 2030 initiative, operated by Bpifrance (1). million (approximately US$1.99 The company said in June 2025 that it raised €11.25 million (US$12.9

Dosage

Fierce Pharma

JUNE 29, 2023

By 2030, Sanofi figures its immunizations could generate more than €10 billion in annual sales, the company said during a vaccines R&D event Thursday. While Dupixent often steals the show, Sanofi isn’t sleeping on its vaccine franchise. |

Vaccines

European Pharmaceutical Review

NOVEMBER 18, 2022

Achieving Immunization Agenda 2030 goals. The report highlighted opportunities for more alignment of vaccine development, production and distribution with a public health agenda, towards achieving the Immunization Agenda 2030 (IA2030) goals and informing pandemic prevention, preparedness and response efforts.

Vaccines

European Pharmaceutical Review

JULY 12, 2023

They do not promote herd immunity and are not generally effective in infants and children younger than two years old. Therefore, having access to this vaccine will “move us closer to defeating meningitis by 2030″ noted the UK’s International Development Minister Andrew Mitchell. However, they only provide short-term protection.

Vaccines

European Pharmaceutical Review

DECEMBER 2, 2022

Vaccines Europe states that the actions must be addressed to ensure the European Beating Cancer Plan and the Immunization Agenda 2030 are met. The organisation claims it is crucial to account for vaccine specificities when shaping Europe’s research ecosystem, through revision of the General Pharmaceutical Legislation.

Vaccines

pharmaphorum

JANUARY 19, 2023

Alopecia areata is an autoimmune disease in which the immune system attacks the body’s hair follicles, causing hair to fall out, predominantly on the scalp, but also sometimes affecting other areas of the body like eyebrows, eyelashes, and facial hair. .” The $11.50

Labelling

pharmaphorum

JUNE 8, 2021

The entire APAC region already accounts for 30% of all global pharma spending, and within these markets national healthcare expenditure is expected to increase threefold to over $2 trillion by 2030. million in 2030. New cancer cases in China increased from 4 million in 2015 to 4.4 million in 2019, and are estimated to increase to 5.7

Chemotherapy

pharmaphorum

MARCH 10, 2022

Biologics product development has increased steadily over the past decade, with the volume of business forecast to double by 2030. Driven by advancements in technology, these complex therapeutics have already made waves in life sciences, providing revolutionary treatment options in oncology, immune conditions and rare diseases.

Pharmaceutical Companies

pharmaphorum

JULY 28, 2021

Under the agreement, Calico is responsible for research and early development until 2025 and will take projects through phase 2a trials until 2030, with AbbVie having an option to take over projects once they reach later-stage development and lead commercialisation efforts.

Immunization

Omnicell

JANUARY 10, 2023

James Stevenson PharmD, FASHP, Chief Clinical Officer, Omnicell The United States faces a shortage of physicians – expected to reach approximately 139,000 by 2030.

Patient Care

Roots Analysis

FEBRUARY 28, 2024

This therapy induces or restores patients’ immune tolerance by establishing stable donor chimerism in the transplant recipient without the need for life-long immunosuppression. The stem cell manufacturing market for CMO is expected to grow at compounded annual growth rate (CAGR) of 18% during the forecast period 2019 – 2030.

Compounding

Roots Analysis

OCTOBER 4, 2023

They are designed to recognize and bind to two specific molecules, such as a tumor cell and an immune cell, or two different parts of the same molecule. Bispecific antibodies are a type of antibody that can bind to two different targets at the same time. during the period 2023-2035.

Chemotherapy

PQA

MARCH 28, 2024

In the coming weeks, we will launch a new pilot to address adult immunization status and gaps in payer-pharmacy arrangements. Utilizing data from five distinct sources, this cutting-edge work will provide standardized evaluation of pharmacy services to improve adult immunization rates.

Immunization

PharmaShots

MARCH 13, 2023

IgA immune complexes are higher in circulation when patients have respiratory infections such as a cough or sore throat, therefore, many of them end up depositing in the kidneys and this is when patients with IgA nephropathy typically present with symptoms such as hematuria (blood in the urine).

Mayo Clinic

European Pharmaceutical Review

MARCH 7, 2024

Firstly, alpha particles exhibit greater biological effectiveness by inducing irreparable DNA double-strand breaks, minimising the risk of resistance or immune escape in tumour cells. However, by employing alpha particles, TAT offers two crucial advantages.

Pharmaceutical Companies

PharmaShots

JUNE 29, 2023

A portmanteau of nutrients and pharmaceuticals, nutraceuticals are colloquially known as medical foods With a market size of $413B in 2021, the nutraceutical market value is forecasted to cross the threshold of $650B by 2030 by marking a remarkable CAGR of 3.9 percent from 2021 to 2030.

Immunization

Pharmaceutical Technology

MAY 25, 2023

The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. The World Health Organization (WHO) has set a goal of ending the meningitis epidemic by 2030.

Vaccines

PharmaShots

APRIL 11, 2023

by 2030 at a CAGR of 6.9% Market Size:4 The global hemophilia market size accounted for $12.2B in 2021 and is projected to increase at $22.2B

Immunization

pharmaphorum

JUNE 1, 2022

According to the World Health Organization, the world will need more than 40 million new doctors, nurses, frontline healthcare workers, and various other healthcare professionals by 2030. This equates to approximately doubling the current medical workforce.

Vaccines

Pharmacy Friday Pearls

MARCH 9, 2022

Crotalidae Polyvalent Immune FAB (Ovine). Crotalidae Immune F(ab’)2 (Equine). 2001;161(16):2030-6. Patients can develop delayed or recurrent hematologic symptoms up to a week after treatment cessation, especially following a severe envenomation. Pharmacology. Cocchio C, et al Am J Health Syst Pharm. 2020;77(3):175-187.

Immunization

The Checkup by Singlecare

OCTOBER 26, 2023

Immunosuppression, or medicines that suppress the immune system, may be necessary. Eating healthy foods rich in iron (such as spinach, red meat, broccoli, chickpeas, and fish) and foods with lots of Vitamin B12 (such as eggs, yogurt, dairy, and turkey) can replace some nutrients in the body. Medications. Dietary supplements.

Immunization

pharmaphorum

JANUARY 10, 2023

Since then, the two partners have developed multiple AI-based applications including a platform for selecting neoantigens for use in individualised cancer vaccines and an early warning system for high risk SARS-CoV-2 variants based on how well they can evade the immune system and their transmissibility.

Immunization

European Pharmaceutical Review

SEPTEMBER 1, 2023

billion by 2030 BioNTech Development of mRNA-based oncology therapies for German biotech BioNTech is progressing. During the American Society of Clinical Oncology (ASCO) 2023 annual meeting, BioNTech revealed promising Phase I results for the pancreatic cancer drug BNT122 combined with the immune checkpoint inhibitor (ICI) atezolizumab.

Immunization

pharmaphorum

JANUARY 6, 2023

The cancer immunotherapies will mainly be provided in the context of clinical trials over the alliance, which extends out to 2030, but also covers supply of commercial therapies if approved in the interim. It will also cover some infectious disease targets.

Vaccines

Pharmacy Times

NOVEMBER 4, 2022

WHO has released a global plan for hepatitis B elimination by 2030, including goals to increase pediatric and maternal immunization and to improve screening and treatment.

Vaccines